Glenmark confirms patent challenge for its generic versions of VIPMAT in US

13 Jul 2013 Evaluate

A suit had been filed against Glenmark Generics, a subsidiary of Glenmark Pharmaceuticals in the United States District Court by UCB INC., UCS Pharma GmbH, Research Corporation Technologies Inc. and Harris FRC Corporation, seeking to prevent Glenmark from commercializing its ANDA product prior to the expiration of US Patent. If Glenmark is successful in its challenge of the patent, it will garner 180-day exclusivity for its products.

Glenmark Generics had filed Abbreviated New Drug Applications (ANDAs) for Lacosamide Tablets, and Oral Solution with the US Food and Drug Administration (USFDA) with a Paragraph IV Certification for the Orange-Book listed patent. Glenmark’s ANDA products are generic versions of VIPMAT.

According to IMS health data for the twelve months ending March 31, 2013, VIPMAT tablets and Solution had total US sales of approximately $353 million.

Glenmark Pharma Share Price

1974.05 17.65 (0.90%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×